A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Pulmonary Arterial HypertensionInterstitial Lung DiseaseHealthy Adults
Interventions
DRUG

Treprostinil

30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.

DIAGNOSTIC_TEST

Right Heart Catheterization (RHC) while exercising

A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.

DIAGNOSTIC_TEST

Optional Muscle Biopsy

A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

United Therapeutics

INDUSTRY

lead

Mayo Clinic

OTHER